Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
bpaddock:todo [2018/11/11 22:26]
bpaddock Herbicide Link
bpaddock:todo [2019/07/29 00:34] (current)
bpaddock Replaced the Bayer Letter with Web Archive.
Line 95: Line 95:
 Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, acute uncomplicated cystitis, and uncomplicated urinary tract infections. Health care professionals should encourage patients to read the Medication Guide that describes the safety issues associated with fluoroquinolones. ​ The Medication Guide is required to be given to the patient with each fluoroquinolone prescription. ​ Stop fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course. ​ Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, acute uncomplicated cystitis, and uncomplicated urinary tract infections. Health care professionals should encourage patients to read the Medication Guide that describes the safety issues associated with fluoroquinolones. ​ The Medication Guide is required to be given to the patient with each fluoroquinolone prescription. ​ Stop fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course. ​
  
-http://​www.bayer.us/​en/​news/​statements/​new-limitations-of-use-and-safety-information-for-fluoroquinolones.php+https://​web.archive.org/​web/​20170619174119/​https://​www.bayer.us/​en/​news/​statements/​new-limitations-of-use-and-safety-information-for-fluoroquinolones.php
  
 Reporting Adverse Events: Reporting Adverse Events: